Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT03683680
Status
Recruiting
Apply to this trial

Conditions

  • Mesothelioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MPT Test — OTHER
    molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
  • CLDN15/VIM Test — OTHER
    molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms

Study Details

This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

Key Dates

Start date
Oct 31, 2018
Status verified
Apr 2026
Primary completion
Jan 1, 2030
Completion
Oct 1, 2030

Study Design

Enrollment
240 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: MRiS
    * The specimens to be collected will include at least five pleural biopsy samples * MPT test and the CLDN15/VIM test will be performed

Primary Outcome Measure

Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02215
Raphael Bueno, MD
[email protected]
617-732-5690
Raphael Bueno, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MA

Related Studies